| Nota de fuente |
Three-year follow-uo of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib, 2015---cub. (John C. Byrd) p. 1 (John C. Byrd, The Ohio State, Columbus)
WWW DNB GND, 30-5-2016---(Byrd, John C.)
|
